Tanja Lahaye

2.3k total citations · 1 hit paper
22 papers, 1.4k citations indexed

About

Tanja Lahaye is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Tanja Lahaye has authored 22 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 17 papers in Genetics and 10 papers in Rheumatology. Recurrent topics in Tanja Lahaye's work include Chronic Myeloid Leukemia Treatments (20 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Eosinophilic Disorders and Syndromes (10 papers). Tanja Lahaye is often cited by papers focused on Chronic Myeloid Leukemia Treatments (20 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Eosinophilic Disorders and Syndromes (10 papers). Tanja Lahaye collaborates with scholars based in Germany, United States and Switzerland. Tanja Lahaye's co-authors include Andreas Hochhaus, Rüdiger Hehlmann, Sebastian Kreil, Claudia Schoch, Ute Berger, Harald Gschaidmeier, Paul La Rosée, A. Corbin, Brian Druker and Nicholas C.P. Cross and has published in prestigious journals such as Blood, Cancer and Annals of the New York Academy of Sciences.

In The Last Decade

Tanja Lahaye

20 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

2002 675 citations Andreas Hochhaus, Sebastian Kreil et al. Leukemia profile →

Peers

Tanja Lahaye

HEMAT

GENET

RHEUM

ONCOL

Franck E. Nicolini France

Manuel Ayala Mexico

Benjamin Hanfstein Germany

Gabriele Gugliotta Italy

Melissa Holtz United States

Angela Poerio Italy

Niove E. Jordanides United Kingdom

Jean-Luc Laı̈ France

J. Chabrol France

Pierre Laneuville Canada

Franck E. Nicolini France

Tanja Lahaye

1.5k ×1.2

HEMAT

1.2k ×1.2

GENET

697 ×0.9

RHEUM

195 ×1.1

253 ×1.8

ONCOL

Citations per year, relative to Tanja Lahaye Tanja Lahaye (= 1×) peers Franck E. Nicolini

Countries citing papers authored by Tanja Lahaye

Since Specialization

Citations

This map shows the geographic impact of Tanja Lahaye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tanja Lahaye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tanja Lahaye more than expected).

Fields of papers citing papers by Tanja Lahaye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tanja Lahaye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tanja Lahaye. The network helps show where Tanja Lahaye may publish in the future.

Co-authorship network of co-authors of Tanja Lahaye

This figure shows the co-authorship network connecting the top 25 collaborators of Tanja Lahaye. A scholar is included among the top collaborators of Tanja Lahaye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tanja Lahaye. Tanja Lahaye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fabarius, Alice, Claudia Haferlach, M. C. Muller, et al.. (2007). Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica. 92(6). 834–837. 29 indexed citations

Rohrbacher, Maren, Ute Berger, Andreas Hochhaus, et al.. (2007). Clinical Trials Underestimate Age of Chronic Myeloid Leukemia (CML) Patients: Epidemiological Study in a Representative Area in Germany.. Blood. 110(11). 2955–2955. 2 indexed citations

Fabarius, Alice, Claudia Schoch, Martin Mueller, et al.. (2006). Dynamics of Cytogenetic Aberrations in Philadelphia Chromosome Positive and Negative Hematopoiesis during Dasatinib Therapy of Chronic Myeloid Leukemia Patients after Imatinib Failure.. Blood. 108(11). 2114–2114. 1 indexed citations

Fabarius, Alice, Michelle Giehl, Alwin Kraemer, et al.. (2006). Centrosome Aberrations, Disturbed Mitotic Spindle Formation and G1 Arrest in Normal and Leukemic Cells Treated with the SRC/ABL Inhibitor Dasatinib.. Blood. 108(11). 2167–2167. 4 indexed citations

Müller, Martin C., Philipp Erben, Thomas Schenk, et al.. (2006). Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.. Blood. 108(11). 748–748. 10 indexed citations

Berger, Ute, Ole Maywald, Markus Pfirrmann, et al.. (2005). Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 19(6). 984–989. 54 indexed citations

Lahaye, Tanja, Ute Berger, Peter Paschka, et al.. (2005). Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center. Cancer. 103(8). 1659–1669. 191 indexed citations

Hochhaus, Andreas, Thomas Ernst, Philipp Erben, et al.. (2005). Long Term Observation of CML Patients after Imatinib Resistance Associated with BCR-ABL Mutations.. Blood. 106(11). 1086–1086. 6 indexed citations

Mueller, Martin, Peter Paschka, Tanja Lahaye, et al.. (2004). Molecular Long-Term Surveillance of CML Patients on Imatinib Therapy. Follow-Up of German Patients Treated within the IRIS Trial.. Blood. 104(11). 1003–1003. 1 indexed citations

10.

Brümmendorf, Tim H., Ulrike Hartmann, Stefan Balabanov, et al.. (2003). Normalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid Leukemia. Annals of the New York Academy of Sciences. 996(1). 26–38. 23 indexed citations

11.

Paschka, Peter, Martin C. Müller, Kirsten Merx, et al.. (2003). Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 17(9). 1687–1694. 65 indexed citations

12.

Ugurel, Selma, Tanja Lahaye, Ralf Hildenbrand, et al.. (2003). Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. British Journal of Dermatology. 149(3). 678–679. 17 indexed citations

13.

Muller, M. C., Kirsten Merx, Sebastian Kreil, et al.. (2002). Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia. 16(12). 2395–2399. 49 indexed citations

14.

Hochhaus, Andreas, Sebastian Kreil, A. Corbin, et al.. (2002). Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16(11). 2190–2196. 675 indexed citations breakdown →

15.

Müller, Martin, Tanja Lahaye, & Andreas Hochhaus. (2002). Resistenz auf tumorspezifische Therapie mit Imatinib durch klonale Selektion mutierter Zellen. DMW - Deutsche Medizinische Wochenschrift. 127(42). 2205–2207. 26 indexed citations

16.

Merx, Kirsten, M. C. Muller, Sebastian Kreil, et al.. (2002). Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α. Leukemia. 16(9). 1579–1583. 124 indexed citations

17.

Brandt, Laura, et al.. (2002). [Systemic infections of dental origin].. PubMed. 103(1). 26–9. 5 indexed citations

18.

Burchert, Andreas, Stefan Wölfl, Manuel Schmidt, et al.. (2002). Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 101(1). 259–264. 109 indexed citations

19.

Kreil, Sebastian, Martin Müller, Tanja Lahaye, et al.. (2001). Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. ePrints Soton (University of Southampton). 16 indexed citations

20.

Lahaye, Tanja. (1999). [Unusual cause of hyponatremia].. PubMed. 88(17). 777–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact